Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removal

Funding supports continued commercial expansion, clinical evidence generation, and ongoing innovation across the CVAC System platform

Apr. 15, 2026 at 4:49am

Got story updates? Submit your updates here. ›

A translucent X-ray image of a human kidney, with the stone fragments glowing against the dark background, conceptually illustrating the complexity and importance of advanced kidney stone treatment technology.Calyxo's CVAC System uses advanced aspiration technology to enable more complete kidney stone clearance, reducing the need for repeat procedures and downstream healthcare costs.Pleasanton Today

Calyxo, Inc., a medical device company focused on improving kidney stone treatment, has announced the closing of a $40 million Series F financing round. The funding will be used to expand the company's commercial infrastructure, advance clinical and health economic evidence generation, and support continued innovation in kidney stone care. The financing follows a key milestone for Calyxo, with the CVAC System, its all-in-one aspiration-based stone removal system, having now treated over 40,000 patients.

Why it matters

Kidney stones are a common and painful condition that can result in significant healthcare costs. Calyxo's CVAC System offers a minimally invasive approach to kidney stone clearance, with clinical data demonstrating improved procedural efficiency and reductions in downstream healthcare utilization and cost. The company's ability to secure this significant funding round reflects the growing recognition of the CVAC System as an important part of the standard of care in kidney stone treatment.

The details

The $40 million Series F financing round was led by Ally Bridge Group and Janus Henderson Investors, with continued support from Calyxo's existing investors Questa Capital, Avidity Partners, and CRG. The CVAC System enables continuous aspiration of stone fragments, supporting more complete stone clearance. Clinical, preclinical, and health economic data have consistently demonstrated low residual stone volume, improved procedural efficiency, and reductions in downstream healthcare utilization and cost.

  • Calyxo's CVAC System was FDA-cleared in 2024.
  • Calyxo has now treated over 40,000 patients with the CVAC System.

The players

Calyxo, Inc.

A medical device company focused on improving care for patients with kidney stones by delivering solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes.

Ally Bridge Group

The lead investor in Calyxo's $40 million Series F financing round, with Kevin Reilly, Managing Director and Head of Medtech, stating that the company is addressing a meaningful need in kidney stone treatment with a differentiated approach supported by strong clinical validation and physician adoption.

Janus Henderson Investors

A co-lead investor in Calyxo's $40 million Series F financing round.

Got photos? Submit your photos here. ›

What they’re saying

“Ally Bridge Group is pleased to lead this financing to support Calyxo's continued growth. The company is addressing a meaningful need in kidney stone treatment with a differentiated approach supported by strong clinical validation and physician adoption. We are excited to partner with the Calyxo team as they continue to build on this momentum.”

— Kevin Reilly, Managing Director, Head of Medtech at Ally Bridge Group

“This financing marks an important inflection point for Calyxo. More than 40,000 patients have now been treated with the CVAC System. Real-world experience, together with an established body of clinical evidence, indicates that the CVAC System is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”

— Joe Catanese, Chief Executive Officer of Calyxo

What’s next

Calyxo plans to use the $40 million in Series F funding to expand its commercial infrastructure, advance clinical and health economic evidence generation, and support continued innovation in kidney stone care.

The takeaway

Calyxo's successful $40 million Series F financing round and the milestone of 40,000 patients treated with its CVAC System demonstrate the growing recognition of the company's innovative approach to kidney stone treatment. By enabling more complete stone clearance and reducing downstream healthcare utilization, the CVAC System is poised to become an increasingly important part of the standard of care for kidney stone patients.